

# Sara Lopez-Tarruella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3643990/publications.pdf>

Version: 2024-02-01

70  
papers

8,498  
citations

136740

32  
h-index

110170

64  
g-index

72  
all docs

72  
docs citations

72  
times ranked

10423  
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. <i>Cancers</i> , 2022, 14, 512.	1.7	2
2	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	5.1	148
3	How we treat HR-positive, HER2-negative early breast cancer. <i>Future Oncology</i> , 2022, 18, 1003-1022.	1.1	11
4	Abstract P1-15-04: Features of HER2+ metastatic patients (pts) from a prospective registry of advanced breast cancer (ABC), GEICAM/2014-03 (RegistEM). <i>Cancer Research</i> , 2022, 82, P1-15-04-P1-15-04.	0.4	0
5	Abstract PD4-08: Breast cancer clinical subtypes in brain metastases patients from a prospective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM). <i>Cancer Research</i> , 2022, 82, PD4-08-PD4-08.	0.4	0
6	The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0. <i>Supportive Care in Cancer</i> , 2022, 30, 6745-6754.	1.0	2
7	Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer. <i>Mathematics</i> , 2021, 9, 222.	1.1	2
8	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
9	Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. <i>Scientific Reports</i> , 2021, 11, 7064.	1.6	13
10	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€”The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	0.8	153
11	DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. <i>Journal of Personalized Medicine</i> , 2021, 11, 792.	1.1	2
12	Technical Challenges for CTC Implementation in Breast Cancer. <i>Cancers</i> , 2021, 13, 4619.	1.7	13
13	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	13.9	363
14	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , 2020, 80, 131-146.	4.9	10
15	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 60-72.	5.1	161
16	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic antiâ€”PD-1 for patients with antiâ€”PD-1â€”refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	51
17	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID â€”19 Pandemic in Spain. <i>Oncologist</i> , 2020, 25, e1339-e1345.	1.9	14
18	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2â€”-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478

#	ARTICLE	IF	CITATIONS
19	Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. <i>Cancer</i> , 2019, 125, 3974-3984.	2.0	67
20	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	6.3	260
21	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Tj ETQq1 1 0.784314 rgBT /Over	1.6	11
22	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.	3.2	84
23	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. <i>Journal of Genetic Counseling</i> , 2018, 27, 854-862.	0.9	5
24	Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase <em>(DPYD)</em> gene. <i>Cancer Management and Research</i> , 2018, Volume 10, 4517-4522.	0.9	4
25	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	3.2	82
26	Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2018, 379, 753-763.	13.9	1,472
27	Simulation modeling approaches to answer clinically relevant questions in breast cancer low-risk populations. <i>Annals of Translational Medicine</i> , 2018, 6, S80-S80.	0.7	0
28	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	3.2	108
29	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 181-189.	1.1	11
30	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. <i>Future Oncology</i> , 2017, 13, 2137-2149.	1.1	7
31	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. <i>Breast Care</i> , 2017, 12, 296-302.	0.8	8
32	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1688-1700.	5.1	451
33	Neratinib for the treatment of HER2-positive early stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 669-679.	1.1	22
34	Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM - El Álamo III retrospective study. <i>PLoS ONE</i> , 2017, 12, e0184181.	1.1	0
35	Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene. <i>Clinical Breast Cancer</i> , 2016, 16, 364-371.	1.1	5
36	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 507-515.	1.1	27

#	ARTICLE	IF	CITATIONS
37	Endocrine therapy for hormone treatment-naïve advanced breast cancer. <i>Breast</i> , 2016, 28, 161-166.	0.9	7
38	S-1 versus taxanes for HER2-negative metastatic breast cancer. <i>Lancet Oncology</i> , The, 2016, 17, 11-12.	5.1	3
39	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. <i>Journal of Clinical Oncology</i> , 2016, 34, 500-500.	0.8	32
40	Emerging Therapeutic Options for HER2-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e64-e70.	1.8	13
41	Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2548-2548.	0.8	0
42	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3995-4003.	3.2	82
43	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1045-1052.	0.8	108
44	Optimizing Adjuvant Taxanes in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2334-2336.	0.8	1
45	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
46	Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 371-382.	1.1	73
47	A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants atDPYDand a putative role forENOSF1rather thanTYMS. <i>Gut</i> , 2015, 64, 111-120.	6.1	93
48	Evaluation of a Heredofamilial Cancer Unit in Increasing Family History Collection and Genetic Counseling Referrals Among Spanish Oncologists at a University Hospital. <i>Journal of Genetic Counseling</i> , 2014, 23, 108-113.	0.9	3
49	Zooming in on the schedule of bone-modifying drugs. <i>Lancet Oncology</i> , The, 2013, 14, 575-576.	5.1	4
50	Maintenance therapy in breast cancer—many questions remain. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 370-372.	12.5	4
51	Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2013, 18, 917-923.	1.9	41
52	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013, 15, R105.	2.2	80
53	Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 903-913.	1.1	41
54	Neratinib (HKI-272) in the treatment of breast cancer. <i>Future Oncology</i> , 2012, 8, 671-681.	1.1	26

#	ARTICLE	IF	CITATIONS
55	Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 583-593.	1.1	31
56	Adjuvant Trastuzumab in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 1273-1283.	13.9	2,254
57	Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 127-136.	1.1	66
58	Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelial ovarian cancer patients. Long-term single institution experience and literature review. <i>Clinical and Translational Oncology</i> , 2011, 13, 121-132.	1.2	8
59	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1873.	3.8	531
60	Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma. <i>Anti-Cancer Drugs</i> , 2010, 21, S19-S22.	0.7	4
61	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 591-600.	1.1	38
62	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5351-5361.	3.2	185
63	Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. <i>Cancer Treatment Reviews</i> , 2009, 35, 335-339.	3.4	94
64	Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer. <i>Breast Cancer Research</i> , 2009, 11, 204.	2.2	27
65	Unravelling the mystery of the TACT trial. <i>Lancet, The</i> , 2009, 373, 1662-1663.	6.3	5
66	Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer. <i>Acta Oncol<span style="font-size: 0.8em; vertical-align: middle;">Á</span>gica</i> , 2008, 47, 1584-1589.	0.8	0
67	The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm. <i>Clinical Cancer Research</i> , 2007, 13, 6921-6925.	3.2	52
68	Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. <i>Lancet Oncology, The</i> , 2007, 8, 219-225.	5.1	181
69	Trastuzumab Associated with Successive Cytotoxic Therapies Beyond Disease Progression in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 325-329.	1.1	46
70	Docetaxel extravasation: a case report. , 2003, 5, 47-48.		0